Services we provide in the field of cell & gene therapy

1. Contracted manufacturing of commercial products (CMO)
Manufacturing of commercial cell & gene therapy products, including CAR-T cells, in our PIC/S GMP-compliant facilities.
2. Process development and manufacturing of clinical products (CDMO)
Research, process development and manufacturing of clinical products, meeting the varied demands of academia, bio-ventures and pharma companies.
3. Quality control testing of CGT products for commercial, clinical and research use
Quality control tests in accordance with the US, EU and Japanese Pharmacopoeia and relevant GLP testing procedures as defined by regulatory agencies.
4. Consultation for regulatory issues
Comprehensive consultation service for issues regarding process development, the manufacturing process, and relevant regulatory issues so as to facilitate clinical trials and the obtaining of market approval.

Company information

NameCyto-Facto Inc.
RepresentativeShin Kawamata, MD, PhD, CEO
Location1-5-4 TRI 3F, Minatojima-minamimachi, Chuo-ku, Kobe, Japan
EstablishmentOctober 18, 2022
Employees68 (as of April 1st, 2023)

Message from Cyto-Facto

The Foundation for Biomedical Research and Innovation at Kobe (FBRI) was established in 2000 as a core organization to support the cluster of bio-medical companies in Kobe, Japan. The Research & Development Center for Cell Therapy (RDC) was established as the fourth center in FBRI in 2015. The goals of the RDC are to ensure the quality of cell products used in cell & gene therapy to facilitate regulatory approval and to provide cell manufacturing services as a CMO/CDMO for domestic and global biotech and pharma companies.


Beginning in April 2023, Cyto-Facto Inc. will take over the business activities of RDC as an FBRI spinout company. Cyto-Facto Inc. will take full responsibility for meeting the demands of society and the healthcare industry for reliable cell & gene therapy products.


We will continuously improve our service and our manufacturing technology to support the health of society by providing quality cell & gene therapy products to patients in a timely manner.

Shin Kawamata, MD, PhD

Chief Executive Officer


If you agree to the Privacy Policy after filling in the inquiry form, please check the "Agree" box at the bottom of the screen and click the "Next" button.

Name ※
Email ※
Email ※
Message ※

■Purpose of entering personal information

This website asks you to enter personal information as a means of confirming the contents of inquiries and estimates regarding services. The personal information entered by the customer will be used within the scope of the purpose of collection specified to the customer. Personal information will not be used for purposes other than those specified to the customer without the customer's consent.  

■Protection and management of personal information

We will strive to protect the personal information entered by our customers under an appropriate and strict management system. Personal information will not be disclosed or transferred to third parties except for the following cases.
1. With your consent
2. When it is necessary to disclose personal information to a subcontractor in order to carry out "Purpose of entering personal information" specified to the customer
3. When subject to law or requested to provide legally enforceable information

The contents of this policy may be revised as necessary. Please check the latest contents of this page when using.